HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2025
0mins
Source: Newsfilter
Development of HB-500: HOOKIPA Pharma, in collaboration with Gilead Sciences, is advancing the next-generation therapeutic vaccine HB-500 for HIV treatment, with enrollment completed for a Phase 1b clinical trial involving 30 participants, expected to conclude by H2 2025.
Vaccine Mechanism and Goals: HB-500 utilizes genetically engineered vectors to deliver HIV antigens aimed at inducing strong immunity, targeting over 80% of circulating HIV-1 variants, as part of a strategy for a potential functional cure for HIV.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
